Related Experiment Video

Updated: Jul 5, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

Marc Ladanyi1, William Pao

  • 1Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. ladanyim@mskcc.org

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|June 24, 2008
PubMed

Insights

Targeted therapies for cancers with specific tyrosine kinase mutations, like epidermal growth factor receptor (EGFR) in lung cancer, are effective. Understanding EGFR mutation testing and resistance is key for guiding treatment decisions.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Somatic mutations in tyrosine kinases drive specific cancers.
  • Mutant proteins are targets for novel therapies.
  • Epidermal growth factor receptor (EGFR) mutations are key drivers in lung adenocarcinoma.

Purpose of the Study:

  • To provide an overview of EGFR-targeted therapies.
  • To discuss clinical experience, predictors of response, and resistance.
  • To cover testing methods for patient eligibility.

Main Methods:

  • Literature review of EGFR-targeted therapies.
  • Analysis of clinical trial data.
  • Review of pathological and resistance mechanisms.

Main Results:

  • EGFR mutation testing guides treatment in lung adenocarcinoma.
  • Predictors of response and resistance are being identified.
  • Understanding resistance mechanisms is crucial for effective therapy.

Conclusions:

  • EGFR-targeted therapies represent a significant advance in lung cancer treatment.
  • Personalized medicine approaches based on molecular profiling are essential.
  • Further research into resistance mechanisms will improve patient outcomes.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...